Prevalence of Left Ventricular Hypertrophy (LVH) in CKD Patients and Effect of Erythropoietin Therapy
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 100
- 主要终点
- Change in LVMI following erythropoietin therapy in anemic CKD patients.
研究概览
简要总结
The goal of this observational study is to determine the prevalence of left ventricular hypertrophy among patients with chronic kidney disease at Sohag University Hospital and assess the effect of erythropoietin therapy on left ventricular mass and geometry in anemic CKD patients.
The main question it aims to answer is:
Does erythropoietin therapy mitigate or even reverse LVH and improve cardiac geometry ?
详细描述
The prevalence of LVH in CKD patients has been reported to range from 40% to 75%, depending on disease stage, blood pressure control, and diagnostic methodology. LVH typically develops early and worsens with CKD progression, reflecting the close interplay between renal dysfunction and cardiac remodeling.
Anemia is a prominent non-hemodynamic contributor to LVH in CKD. Reduced erythropoietin (EPO) production by the damaged kidneys, together with iron deficiency and chronic inflammation, leads to decreased oxygen delivery, compensatory cardiac output elevation, and subsequent ventricular hypertrophy.
Given the strong association between CKD, anemia, and cardiovascular remodeling, investigating the prevalence of LVH and the effect of erythropoietin therapy on left ventricular mass among CKD patients can provide critical insights into optimizing cardiovascular risk management in this high-risk group.
this study will be conducted to :
- To determine the prevalence of left ventricular hypertrophy among patients with chronic kidney disease at Sohag University Hospital.
- To assess the effect of erythropoietin therapy on left ventricular mass and geometry in anemic CKD patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults (≥18 years) diagnosed with CKD stages 3-
- •Stable clinical condition for ≥3 months.
- •Anemia (Hb <10 g/dL) for cohort phase.
- •Willingness to participate and provide informed consent.
排除标准
- •Valvular or ischemic heart disease.
- •Uncontrolled hypertension (BP >180/110 mmHg).
- •Acute coronary syndrome or decompensated heart failure in the past 3 months.
- •Malignancy or active infection
结局指标
主要结局
Change in LVMI following erythropoietin therapy in anemic CKD patients.
时间窗: - baseline transthoracic echocardiography will be performed for all group study.
次要结局
- Association between hemoglobin level and LVMI.(6 months of erythropoitin therapy , transthoracic echocardiography will be performed for all group study.)
研究者
Khaled Mohamed Mohamedin
resident of internal medicine
Sohag University